HKEX: 6998
Next Day Disclosure Return
Earlier from Edding Genor
- 2026 Interim Report
- Edding Genor: EDG Announced Phase Ib/II Clinical Trial of GB268 Obtained IND Approval by NMPA
- Edding Genor: EDG Announced EDP167 has successfully completed the first subject dosing in its Phase II clinical trial
- Genor Biopharma: Releases Its Interim Results for 2023